Fig. 5: Therapeutic vaccination with CRX-527 conjugates results in effective therapeutic activity.

a Schematic overview of the experiment. Mice (n = 10 per group) were injected with 100,000 B16OVA tumor cells. Once tumors were palpable, mice were vaccinated with 1 nmol of CRX-527, a mixture of CRX-527 and OVA CTL and Help peptides or the two OVA CTL and Help conjugates. Blood was withdrawn at day 18 to monitor the induction of SIINFEKL-specific CD8 responses by tetramer staining. b Average (±SD) B16OVA tumor growth in the different therapeutic vaccination groups. Statistical significance between Lipid A, mix and conjugates at different time points was calculated by one-way ANOVA and Tukey’s multiple comparison. The color of the stars indicates to which group the statistical significance is referred to. *p < 0.05, **p < 0.01. c Overall survival of mice therapeutically vaccinated with CRX-527or OVA CTL and Help peptides in form of mix with CRX-527 or conjugates. Statistical significance was determined by Log-rank Mantel–Cox test; *p < 0.05, ** p < 0.01. d Schematic representation of prophylactic or therapeutic vaccination experiment with HPV E7 specific CRX-527 conjugates against TC-1 tumor. Mice (n = 10 per group) were vaccinated either before (orange syringes) or after (green syringes) TC-1 tumor inoculation and tumor growth and survival were monitored for 80 days. e Individual tumor growth of unvaccinated (gray), prophylactically vaccinated (orange) and therapeutically vaccinated (green) mice and f their corresponding survival plot. Statistical significance was determined by Log-rank Mantel–Cox test; ****p < 0.0001.